Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...
"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity." ...
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...
The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...
The U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea ...
Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...
In the trial that Lilly, the drug's manufacturer, submitted in April to the FDA, scientists reported that the drug helped ...
"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...
In April and December of 2022, respectively, the FDA determined that semaglutide and tirzepatide were in short supply, opening the floodgates for compounding pharmacies and outsourcing facilities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback